EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping

Made Harumi Padmaswari, Shilpi Agrawal iD, Christopher E Nelson

Journal of Neuromuscular Diseases · 2025

DOI: 10.1177/22143602251326993 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neuromuscular Diseases, 2025. Verfasst von Made Harumi Padmaswari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Gene Editing, Exons, Oligonucleotides, Antisense. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) is caused by loss-of-function mutations to the gene encoding dystrophin. Restoring the reading frame of dystrophin by removing internal out-of-frame exons may address symptoms of DMD. Therefore, the principle of exon skipping has been at the center stage in drug development for Duchenne muscular dystrophy (DMD) over the past two decades. Antisense oligonucleotides (AONs) have proven effective in modulating splicing sites for exon skipping, resulting in the FDA approval of several drugs using this technique in recent years. However, due to the temporary nature of AON, researchers are actively exploring genome editing as a potential long-term, single-administration treatment. The advancements in genome-editing technology over the last decade have boosted this transition. While no clinical trials for exon skipping in DMD via genome editing have been conducted as of this writing, preclinical studies show encouraging results. This review describes the preclinical landscape of genome editing for exon skipping in DMD treatment. Along with highlighting the adaptability of genome editing in exon skipping, this review also describes delivery challenges and outlines future research directions that could set a new stage for enhanced therapeutic development in DMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneGene EditingExonsOligonucleotides, AntisenseGenetic TherapyHumansAnimalsDystrophin

Stichwörter der Autor:innen

AAVCRISPRDMDexon skippinggenome editing

Substanzen

Oligonucleotides, AntisenseDystrophin

Autor:innen und Institutionen

  • Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA.
  • Cell and Molecular Biology, University of Arkansas, Fayetteville, AR, USA.

ORCID-Profile: Shilpi Agrawal

Zitieren

APA

Padmaswari, M. H., Agrawal, S., & Nelson, C. E. (2025). Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping. Journal of Neuromuscular Diseases. https://doi.org/10.1177/22143602251326993

Vancouver

Padmaswari MH, Agrawal S, Nelson CE. Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping. Journal of Neuromuscular Diseases. 2025. doi:10.1177/22143602251326993

BibTeX
@article{Padmaswari2025,
  author = {Padmaswari, Made Harumi and Agrawal, Shilpi and Nelson, Christopher E},
  title = {Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping},
  journal = {Journal of Neuromuscular Diseases},
  year = {2025},
  doi = {10.1177/22143602251326993}
}
Kostenlos starten →